CLGN Stock Analysis: Buy, Sell, or Hold?
CLGN - CollPlant Biotechnologies Ltd Ordinary Shares
$0.30
-0.01 (-4.34%)
▼
5d:
-7.2%
30d:
-28.89%
90d:
-27.22%
HOLD
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 19, 2026
14d
Get Alerted When CLGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CLGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CLGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CLGN is currently trading at $0.30, which is considered oversold relative to its 30-day fair value range of $0.31 to $0.37. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.8) compared to its historical average (3.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.27, while resistance sits at $0.35. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: CLGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.12 (+3396.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.27, while resistance sits at $0.35. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: CLGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.12 (+3396.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.31 -
$0.37
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 3396.9% below Wall St target ($11.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: 5-day price weakness (-7.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.31 -
$0.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.27
Resistance Level
$0.35
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.77
Wall Street Target
$11.12
(+3396.9%)
Revenue Growth (YoY)
-96.4%
PE vs Historical
-1.8 vs 3.5
CHEAP
Share & Embed Analysis
Last updated: August 04, 2026 11:26 AM ET
Data refreshes hourly during market hours. Next update: 12:26 PM
Data refreshes hourly during market hours. Next update: 12:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 59 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 42 HOLD |
